Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

TRY MEDICS ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 2.7% 2.7%   Bankruptcy risk   6.0% 6.1% 14.0% 7.3% 10.6% 3.7% 10.7% 10.5%   Credit score (0-100)   40 40 15 32 22 51 23 23   Credit rating   BBB BBB BB BBB BB BBB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   3,148 1,790 487 850 3,169 1,136 0.0 0.0   EBITDA   2,487 1,018 -239 247 2,559 521 0.0 0.0   EBIT   2,487 1,018 -239 247 2,559 521 0.0 0.0   Pre-tax profit (PTP)   2,423.4 1,152.7 -296.3 267.6 2,575.3 595.1 0.0 0.0   Net earnings   1,889.7 895.7 -305.0 208.7 2,013.0 464.1 0.0 0.0   Pre-tax profit without non-rec. items   2,423 1,153 -296 268 2,575 595 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   2,442 1,688 283 492 2,505 1,469 959 959   Interest-bearing liabilities   70.1 173 9.5 1.4 114 1.4 0.0 0.0   Balance sheet total (assets)   6,338 5,529 1,869 4,317 6,258 5,298 959 959   Net Debt   -3,748 -4,252 -870 -3,564 -5,504 -4,953 -959 -959     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   3,148 1,790 487 850 3,169 1,136 0.0 0.0   Gross profit growth   33.2% -43.1% -72.8% 74.7% 272.6% -64.1% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   6,338 5,529 1,869 4,317 6,258 5,298 959 959   Balance sheet change%   9.0% -12.8% -66.2% 130.9% 44.9% -15.3% -81.9% 0.0%   Added value   2,486.9 1,018.2 -238.7 246.7 2,559.2 520.8 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 -1.0 1.0 2.0 3.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   79.0% 56.9% -49.0% 29.0% 80.8% 45.8% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   40.1% 19.7% -5.9% 8.7% 49.2% 10.3% 0.0% 0.0%   ROI %   104.3% 53.5% -16.0% 27.7% 140.8% 29.1% 0.0% 0.0%   ROE %   82.6% 43.4% -30.9% 53.9% 134.4% 23.4% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   76.3% 74.6% 27.1% 39.4% 67.5% 87.9% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -150.7% -417.6% 364.4% -1,444.6% -215.1% -951.0% 0.0% 0.0%   Gearing %   2.9% 10.3% 3.4% 0.3% 4.6% 0.1% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   28.8% 14.5% 86.7% 0.0% 43.4% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   8.4 9.6 9.4 24.7 8.3 26.2 0.0 0.0   Current Ratio   1.6 1.4 1.8 1.3 1.9 1.4 0.0 0.0   Cash and cash equivalent   3,817.8 4,425.6 879.2 3,565.0 5,618.1 4,954.3 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   2,442.5 1,688.1 847.4 1,074.6 2,956.2 1,456.4 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   2,487 1,018 -239 247 2,559 521 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   2,487 1,018 -239 247 2,559 521 0 0   EBIT / employee   2,487 1,018 -239 247 2,559 521 0 0   Net earnings / employee   1,890 896 -305 209 2,013 464 0 0